Abstract
The approval of therapeutic agents that are tested in patients deemed ineligible for intensive or aggressive therapy is increasingly popular. This approach enables comparisons of novel therapies with less-aggressive agents, as well as data from nonrandomized studies to be used for market authorization. Herein, we discuss three mechanisms that could be adopted to avoid the temptation of applying this strategy excessively.
Original language | English (US) |
---|---|
Journal | Nature Reviews Clinical Oncology |
DOIs |
|
State | Published - Jan 1 2019 |
ASJC Scopus subject areas
- Oncology